CA3127175C - Use of topical braf inhibitor compositions for treatment of radiation dermatitis - Google Patents

Use of topical braf inhibitor compositions for treatment of radiation dermatitis Download PDF

Info

Publication number
CA3127175C
CA3127175C CA3127175A CA3127175A CA3127175C CA 3127175 C CA3127175 C CA 3127175C CA 3127175 A CA3127175 A CA 3127175A CA 3127175 A CA3127175 A CA 3127175A CA 3127175 C CA3127175 C CA 3127175C
Authority
CA
Canada
Prior art keywords
grade
rtog
composition
nci
ctcae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3127175A
Other languages
English (en)
French (fr)
Other versions
CA3127175A1 (en
Inventor
Noa Shelach
Noa LOWENTON-SPIER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lutris Pharma Ltd
Original Assignee
Lutris Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lutris Pharma Ltd filed Critical Lutris Pharma Ltd
Publication of CA3127175A1 publication Critical patent/CA3127175A1/en
Application granted granted Critical
Publication of CA3127175C publication Critical patent/CA3127175C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3127175A 2019-02-12 2020-02-11 Use of topical braf inhibitor compositions for treatment of radiation dermatitis Active CA3127175C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962804235P 2019-02-12 2019-02-12
US62/804,235 2019-02-12
PCT/IB2020/051073 WO2020165755A1 (en) 2019-02-12 2020-02-11 Use of topical braf inhibitor compositions for treatment of radiation dermatitis

Publications (2)

Publication Number Publication Date
CA3127175A1 CA3127175A1 (en) 2020-08-20
CA3127175C true CA3127175C (en) 2023-06-27

Family

ID=72044789

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3127175A Active CA3127175C (en) 2019-02-12 2020-02-11 Use of topical braf inhibitor compositions for treatment of radiation dermatitis

Country Status (17)

Country Link
US (1) US11439648B2 (OSRAM)
EP (1) EP3923911B1 (OSRAM)
JP (1) JP2022519675A (OSRAM)
KR (1) KR102534457B1 (OSRAM)
CN (1) CN113382717A (OSRAM)
AU (1) AU2020220895B9 (OSRAM)
BR (1) BR112021015137A2 (OSRAM)
CA (1) CA3127175C (OSRAM)
ES (1) ES2952251T3 (OSRAM)
HR (1) HRP20231241T1 (OSRAM)
HU (1) HUE063091T2 (OSRAM)
IL (1) IL285560B2 (OSRAM)
MX (1) MX2021009535A (OSRAM)
PL (1) PL3923911T3 (OSRAM)
RS (1) RS64618B1 (OSRAM)
WO (1) WO2020165755A1 (OSRAM)
ZA (1) ZA202106581B (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3203021A1 (en) * 2020-12-24 2022-06-30 Noa Shelach Topical braf inhibitor compositions for treatment of egfr downstream effectors - induced reactions
MX2024000227A (es) * 2021-07-02 2024-04-16 Lutris Pharma Ltd Uso de isoquinolina-1,5-diaminas para la curacion de heridas.
CN118139621A (zh) * 2021-09-30 2024-06-04 北京大学 一种对红系前体细胞或成红细胞进行扩增的方法及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753612A (en) 1992-10-27 1998-05-19 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
WO2008153947A2 (en) 2007-06-07 2008-12-18 Amgen Inc. Heterocyclic compounds as raf kinase modulators
PL2947072T3 (pl) * 2008-03-17 2017-05-31 Ambit Biosciences Corporation 1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych
WO2011117381A1 (en) * 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh B-raf kinase inhibitors
US20130226549A1 (en) 2012-02-27 2013-08-29 Yufeng J. Tseng Structure-based fragment hopping for lead optimization and improvement in synthetic accessibility
KR20140011780A (ko) 2012-07-19 2014-01-29 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
JP2017514866A (ja) * 2014-05-06 2017-06-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｂｒａｆ阻害剤を使用する創傷治癒
ES2947237T3 (es) * 2016-03-10 2023-08-03 Lutris Pharma Ltd Uso de inhibidores de BRaf para el tratamiento de reacciones cutáneas
WO2019026065A2 (en) * 2017-07-29 2019-02-07 Lutris Pharma Ltd. NOVEL BRAF INHIBITORS AND THEIR USE FOR THE TREATMENT OF SKIN REACTIONS
WO2019032717A1 (en) * 2017-08-08 2019-02-14 Memorial Sloan Kettering Cancer Center USE OF BRAF INHIBITORS FOR TREATING SKIN REACTIONS CAUSED BY TREATMENT WITH MEK INHIBITOR

Also Published As

Publication number Publication date
AU2020220895B2 (en) 2022-11-17
HUE063091T2 (hu) 2024-01-28
AU2020220895A1 (en) 2021-08-12
IL285560B2 (en) 2024-04-01
ZA202106581B (en) 2022-09-28
EP3923911A1 (en) 2021-12-22
RS64618B1 (sr) 2023-10-31
MX2021009535A (es) 2022-10-10
AU2020220895B9 (en) 2023-02-02
US20210346389A1 (en) 2021-11-11
CA3127175A1 (en) 2020-08-20
PL3923911T3 (pl) 2023-12-27
JP2022519675A (ja) 2022-03-24
US11439648B2 (en) 2022-09-13
WO2020165755A1 (en) 2020-08-20
IL285560B1 (en) 2023-12-01
KR102534457B1 (ko) 2023-05-18
BR112021015137A2 (pt) 2021-09-28
EP3923911C0 (en) 2023-07-12
KR20210126665A (ko) 2021-10-20
EP3923911A4 (en) 2022-11-09
IL285560A (en) 2021-09-30
CN113382717A (zh) 2021-09-10
ES2952251T3 (es) 2023-10-30
EP3923911B1 (en) 2023-07-12
HRP20231241T1 (hr) 2024-02-16

Similar Documents

Publication Publication Date Title
US11439648B2 (en) Use of topical BRAF inhibitor compositions for treatment of radiation dermatitis
JP5389980B2 (ja) 手足症候群の治療のためのアロプリノールの使用
KR20220136979A (ko) 콜히친을 포함하는 알레르기성 피부 질환 또는 피부 소양증 치료용 조성물
WO2013146913A1 (ja) Ｈｄｃ活性化阻害剤、ｈｄｃ活性化阻害剤組成物、鎮痒剤及び鎮痒剤組成物
KR20230139402A (ko) 염증성 피부 증후군을 치료하는 약제학적인 용도의 화장품 조성물
RU2812708C2 (ru) Применение композиций на основе ингибитора braf для наружного применения для лечения лучевого дерматита
HUT74448A (en) Process for preparing pharmaceutical compns. contg. ibuprofen and flurbiprofen for use as anti-pruritic agents
AU2020282051B2 (en) Composition containing fluoxetine and vitamin D 3 or its derivatives and application thereof
KR20080011280A (ko) 피부과학적 질병의 치료를 위한 피부과학적 조성물 및 염
JP5460766B2 (ja) 外用医薬組成物
US20250114362A1 (en) Methods and compositions for treatment of cutaneous proliferative disorders and other skin conditions
US20200046703A1 (en) Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents
EP3573621A1 (en) Glycopeptide derivatives for use in the treatment and/or prevention and/or attenuation of fibrosis diseases
KR20260003504A (ko) 동백나무씨오일, 코코넛야자오일, 또는 이들의 혼합물을 포함하는 반려동물 눈물 착색 억제 및 피모 케어용 조성물
KR20250108066A (ko) 튜불린 저해제를 포함하는 병용요법을 이용한 피부 질환 예방 또는 치료용 조성물
JP2004035422A (ja) 皮膚の劣化の予防および／または低減における次没食子酸ビスマスの使用
HK40017100A (en) Composition for preventing or treating sleep disorders
PL211459B1 (pl) Zastosowanie czwartorzędowych soli pirydyniowych oraz preparat farmaceutyczny zawierający czwartorzędowe sole pirydyniowe

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220314

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - SMALL

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250203

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250203

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250203

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - SMALL

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260203

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260203